How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/septicemia-due-to-escherichia-coli.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Septicemia due to Escherichia coli — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Septicemia due to Escherichia coli (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Septicemia due to Escherichia coli, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Cipro	ciprofloxacin	Bayer AG	Fluoroquinolone antibiotic	DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A	1987-10-22
Azactam	AZTREONAM	Bristol-Myers Squibb	Monobactam Antibacterial [EPC]		1986-01-01
Fortaz	Ceftazidime	Pai Holdings Pharm	Third-generation cephalosporin	Bacterial cell wall	1985-01-01
Rocephin	ceftriaxone	Generic (originally Roche)	Cephalosporin antibiotic (third-generation)	Alpha-synuclein, D-amino-acid oxidase, Penicillin-binding protein 1A	1984-12-21
Augmentin 250	CLAVULANIC ACID	Dr Reddys Labs Inc	beta Lactamase Inhibitor		1984-01-01
Zinacef	CEFUROXIME	GSK	Cephalosporin Antibacterial	Carbonic anhydrase 2	1983-01-01
Arikayce Kit	AMIKACIN	Bristol-Myers Squibb	Aminoglycoside Antibacterial		1981-01-01
Claforan	CEFOTAXIME	Sterimax	Cephalosporin Antibacterial		1981-01-01
Cefaprin	cefapirin	Bristol-Myers Squibb	cefapirin	Sigma non-opioid intracellular receptor 1	1974-01-01
Vantobra	Tobramycin Sulfate	Pfizer	tobramycin	Taste receptor type 2 member 20	1974-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 10 drugs in Septicemia due to Escherichia coli
Bristol-Myers Squibb · 4 drugs in Septicemia due to Escherichia coli
Merck & Co. · 2 drugs in Septicemia due to Escherichia coli
Pai Holdings Pharm · 2 drugs in Septicemia due to Escherichia coli
Centre Hospitalier Universitaire Vaudois · 1 drug in Septicemia due to Escherichia coli
Dr Reddys Labs Inc · 1 drug in Septicemia due to Escherichia coli
GSK · 1 drug in Septicemia due to Escherichia coli
Generic (originally Roche) · 1 drug in Septicemia due to Escherichia coli
Assistance Publique - Hôpitaux de Paris · 1 drug in Septicemia due to Escherichia coli
Novartis · 1 drug in Septicemia due to Escherichia coli
University Hospital, Lille · 1 drug in Septicemia due to Escherichia coli
Pfizer · 1 drug in Septicemia due to Escherichia coli

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Septicemia due to Escherichia coli:

Cite this brief

Drug Landscape (2026). Septicemia due to Escherichia coli — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/septicemia-due-to-escherichia-coli. Accessed 2026-06-10.

Septicemia due to Escherichia coli full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing